We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Commercial System Effective for Cefiderocol Susceptibility Testing

By LabMedica International staff writers
Posted on 11 Jul 2019
The novel formulation of the cephalosporin antibiotic makes it very effective against gram-negative non-fastidious bacteria that are otherwise highly resistant to antibiotics, including carbapenem-resistant strains of Enterobacteriaceae and non-fermenters.

In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.

An international team of scientists working with Thermo Fisher Scientific (Cleveland, Ohio, USA) conducted a study that involved 374 recent clinical isolates, which included Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumannii. One of the four study sites additionally used 147 Centers for Disease Control and Prevention challenge isolates. Three sites also used 11 reproducibility isolates, with three of these isolates being tested each day for three days. Finally, all four sites tested two quality control strains: E. coli ATCC 25922 and P. aeruginosa ATCC 27853.

The team tested a commercially prepared dried minimum inhibitory concentration (MIC) susceptibility system, the Thermo Fisher Scientific Sensititre, and demonstrated an equivalent level of performance compared with the Clinical & Laboratory Standards Institute (CLSI) M07/M100 and the International Organization for Standardization (ISO) 20776-1 reference broth microdilution (BMD) method when testing cefiderocol against Gram-negative non-fastidious organisms.

Overall agreement for the reproducibility (± 1 log2 dilution) concerning the most frequent (or modal) MIC value using automated and manual reading was 95.0% and 95.3%, respectively. The lowest agreement between the two test methods was 90.0% for Enterobacter spp., followed by 92.0% for Citrobacter spp. The strongest agreement was for P. aeruginosa (97.5%). The agreement among the four testing sites was high, at about 95%.

Thomas C. Lewis, BSc, a Research and Development Project Leader at Thermo Fisher Scientific, said, “The high level of agreement obtained by the Sensititre susceptibility system and the CLSI/ISO BMD method suggests that this is an acceptable method for susceptibility testing of cefiderocol. The results are available within 18 to 24 hours, versus several days for the broth. Plus, the testing materials can be kept on the laboratory shelf at room temperature before being used, which is a lot more convenient.” The study was presented at the Annual meeting of the American Society of Microbiology, held June 7-11, 2019, in Atlanta, GA, USA.

Related Links:
Thermo Fisher Scientific


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.